Empagliflozin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Empagliflozin: From Type 2 Diabetes Mellitus to Focal Stiff Limb Syndrome
One-Sentence Summary
Empagliflozin is an SGLT2 inhibitor originally used to treat type 2 diabetes mellitus. The TxGNN model predicts it may be effective for Focal Stiff Limb Syndrome, but this is a model prediction only, with 0 clinical trials and 0 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus |
| Predicted New Indication | Focal stiff limb syndrome |
| TxGNN Prediction Score | 99.06% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 8 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Empagliflozin is known as an SGLT2 inhibitor that lowers blood glucose by reducing glucose reabsorption in the kidney. Its efficacy in type 2 diabetes is established.
No plausible mechanistic link to the predicted indication has been identified. Focal stiff limb syndrome is related to the stiff person spectrum, a neurological/autoimmune disorder involving GAD65 and impaired GABAergic/glycinergic signalling. SGLT2 inhibition has no known action on this pathway. The high score (0.99) most likely reflects associations within the knowledge graph (for example, anti-GAD autoimmunity overlapping with diabetes) rather than a therapeutic rationale.
The other top predictions share the same weakness. Classic stiff person syndrome (99.06%), opsismodysplasia (99.03%), thiamine-responsive dysfunction syndrome (98.99%), and several localized lipodystrophies (98.0–98.5%) appear to be driven by diabetes-related graph associations. Pancreatic agenesis (98.07%) is the only one with any retrieved literature, and those papers concern type 2 diabetes and diabetic retinopathy, not pancreatic agenesis. Empagliflozin is also not appropriate in insulin-deficient states because of ketoacidosis risk.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
No literature directly supports the lead prediction (focal stiff limb syndrome). The only literature retrieved for any of the top 10 predictions relates to pancreatic agenesis (rank 9) and is indirect:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26583910 | 2015 | Review | Expert Opin Pharmacother | Empagliflozin plus linagliptin combination therapy in type 2 diabetes; does not address pancreatic agenesis |
| 35234250 | 2022 | Preclinical/Mechanistic | Biosci Rep | Role of SGLT2 inhibition with empagliflozin in diabetic retinopathy; does not address pancreatic agenesis |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN14687P | JARDIANCE Film-Coated Tablet 25mg | Film-coated tablet | Not specified |
| SIN14686P | JARDIANCE Film-Coated Tablets 10mg | Film-coated tablet | Not specified |
| SIN15061P | JARDIANCE DUO Film-Coated Tablet 12.5mg/1000mg | Film-coated tablet | Not specified |
| SIN15273P | GLYXAMBI Film-Coated Tablets 10mg/5mg | Film-coated tablet | Not specified |
| SIN15272P | GLYXAMBI Film-Coated Tablets 25mg/5mg | Film-coated tablet | Not specified |
Eight valid registrations in total; the five above are shown.
Safety Considerations
- Drug Interactions: An interaction screen returned 100 potential interactions. Most of those reviewed are of Moderate severity, and a few are Minor. Examples of Moderate interactions include:
- Sympathomimetics and bronchodilators: phenylephrine, pseudoephedrine, epinephrine, salbutamol, formoterol
- Cardiovascular and diuretic agents: acebutolol, nifedipine, fosinopril, furosemide, acetazolamide
- Others: ethinylestradiol, hydrocortisone, ethanol, fosphenytoin, gemifloxacin
- Minor: topical hydrocortisone and topical alclometasone
For warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score. There are no clinical trials or supporting literature, and no plausible mechanistic link between SGLT2 inhibition and focal stiff limb syndrome. The same applies to the other top nine predictions.
To proceed, the following is needed:
- Mechanism of action data for empagliflozin
- Package insert warnings and contraindications from the HSA, which are needed before any safety screening
- A documented biological rationale linking SGLT2 inhibition to GABAergic or autoimmune neurological pathways, supported by preclinical data
- Any clinical or observational evidence in stiff person spectrum disorders
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.